Cancer Immunotherapy Drugs Market to Surpass USD 100 Bn by 2022, Expects Industry Experts in Its Study Now Available at MarketPublishers.com
08 Nov 2017 • by Natalie Aster
LONDON – The cancer therapeutics market space is valued at USD 100 billion worldwide, in which the immunotherapeutic drugs have got widespread use from pole to pole. This is due to the fact that they are targeted therapies that have a high level of specificity for tumour cells. Today, cancer immunotherapy drugs have grabbed close to 50% of the total oncology drugs marketplace, generating nearly USD 54 billion in revenue in 2016 alone, and are projected to go beyond the USD 100 billion mark by 2022.
Insightful market research study “Global Cancer Immunotherapy Market Analysis & Forecast to 2022” drawn up by Industry Experts provides a profound, unbiased analysis of the evolution of the market on a worldwide scale.
The report gives an overview of cancer immunotherapy, limelights the current trends in cancer immunotherapies, provides deep insights into the challenges drug developers are facing, offers descriptions of over 23 approved cancer immunotherapeutics used as targeted drugs, sheds light on the different immunotherapeutics available for certain types of cancer. It gives data on the prevalence rates of cancer types addressed by cancer immunotherapeutics. The research report provides an all-round analysis of the world cancer therapeutics market, leading market players and the best selling cancer drugs. It offers granular segmentation analysis of the market by indication, company, individual drugs, and geography-wise. The study presents profiles of marketed products and products in development of 79 global companies. It contains a summary table that helps to identify the category of immunotherapy drug provided by the companies discussed. It gives a brief overview of the CAR-T industry detailing production, regulations and pricing.
Visit Industry Experts online page at MarketPublishers.com to get access to many other topical research reports by this publisher.